Picture loading failed.

Anti-FOLH1;CD3E therapeutic antibody (Pre-made Pasotuxizumab biosimilar,Bispecific scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Pasotuxizumab is a PSMA x CD3 BiTE immune therapy that mediates killing of tumor cells by T cells.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-429-1mg 1mg 3090
GMP-Bios-ab-429-10mg 10mg 21890
GMP-Bios-ab-429-100mg 100mg 148000
GMP-Bios-ab-429-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-FOLH1;CD3E therapeutic antibody (Pre-made Pasotuxizumab biosimilar,Bispecific scFv)
INN Name Pasotuxizumab
TargetFOLH1;CD3E
FormatBispecific scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2014
Year Recommended2015
CompaniesAmgen;Bayer HealthCare Pharmaceuticals;Micromet Inc
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedProstate cancer
Development Techna